Estrogen receptor signaling: nootropics and compounds | sci-wiki

Y-134

Y-134 is a research-stage selective estrogen receptor modulator (SERM) engineered by fine-tuning the well-known drug raloxifene. Beyond the classic SERM profile of blocking estrogen in breast tissue while supporting bone, Y-134 carries a striking bonus: it switches on the aryl hydrocarbon receptor (AhR) and drives even hard-to-treat triple-negative breast cancer cells into programmed cell death, an effect its parent compound only hinted at. Elegant and highly selective, it is prized as a research tool, though it remains preclinical with no human data.

1 outlet

SERM

4-Hydroxytamoxifen

4-Hydroxytamoxifen (afimoxifene, 4-OHT) is the potent active metabolite of tamoxifen and one of the most powerful selective estrogen receptor modulators available, binding the estrogen receptor with far greater affinity than tamoxifen itself. Prized across clinical research and hormonal management, it shuts down estrogen signaling in breast tissue while behaving tissue-selectively elsewhere. It is also a cornerstone laboratory reagent, valued for switching on tamoxifen-inducible genetic systems with precision.

1 outlet

SERM

Endoxifen

Endoxifen is the most potent active metabolite of the breast cancer drug tamoxifen, a powerful antiestrogen that does much of tamoxifen's real work inside the body [1]. Because the body relies on the enzyme CYP2D6 to make it, blood endoxifen levels vary widely between people and strongly predict how well tamoxifen works, which has driven efforts to monitor levels and to give endoxifen directly as a drug [2][3]. For precision in estrogen-driven disease, endoxifen is a compound of intense and growing clinical interest.

1 outlet

Nootropic

DHED

DHED (10-beta,17-beta-dihydroxyestra-1,4-dien-3-one) is an experimental bioprecursor prodrug of the estrogen 17-beta-estradiol that is inert at estrogen receptors until it is converted to the active hormone. Its defining feature is a striking tissue selectivity: a reductase reaction that occurs in nervous tissue regenerates estradiol within the brain and retina after systemic or topical dosing, while the molecule remains unchanged in the periphery, so it does not raise circulating estrogen or stimulate the uterus, breast, or pituitary. In rodent models this brain-restricted delivery has relieved menopausal and androgen-deprivation hot flushes, provided neuroprotection after stroke, and, as eye drops, preserved retinal ganglion cells and visual function in glaucoma models. DHED remains a preclinical agent, but it exemplifies a prodrug strategy aimed at capturing estrogen's central benefits while avoiding the systemic risks that limit conventional hormone therapy.

reference